Fosamax (Alendronate) Side Effects: Real User Reports, Reddit Reviews, and What the Clinical Evidence Actually Shows

Does Fosamax Actually Work? What the Clinical Evidence Shows

Alendronate does work, and the evidence is unusually strong for a bone drug. The Fracture Intervention Trial (FIT), published in JAMA 1998, enrolled 2,027 postmenopausal women with low bone density and found a 47 percent reduction in morphometric vertebral fractures over three years in the alendronate group versus placebo. Hip fracture risk dropped by 51 percent in women who already had a prevalent vertebral fracture at baseline.

The drug works by binding tightly to hydroxyapatite crystals in bone and inhibiting osteoclast-mediated bone resorption. In practical terms, it slows the teardown side of bone remodeling, letting bone density recover. Bone mineral density (BMD) at the lumbar spine increases by roughly 8 percent over three years on the 10 mg daily regimen used in FIT.

What the Evidence Does Not Show

FIT enrolled predominantly white postmenopausal women in their mid-60s. Data in Black, Asian, and Hispanic postmenopausal women, as well as in younger perimenopausal women, is largely extrapolated rather than directly studied. Women have been under-represented in fracture-endpoint bisphosphonate trials more broadly, though the FIT cohort itself was female-only, which is one reason it remains the reference trial for this drug.

How Long Should You Take It?

The American College of Obstetricians and Gynecologists (ACOG) recommends reassessing fracture risk after 3 to 5 years of bisphosphonate therapy before deciding whether to continue, take a drug holiday, or switch agents. Women with very high fracture risk may benefit from continuing past five years, but the data on long-term benefit beyond ten years is thin.

What Real Users Say: Synthesizing Reddit, Drugs.com, and Patient Forum Reports

Online reviews of Fosamax are dominated by negative experiences. This is not unique to this drug. People who tolerate a weekly pill without incident rarely log onto a patient forum to say so. Keep that selection bias in mind as you read every quote below.

The Sample-Size Problem

Drugs.com currently lists several hundred user reviews for alendronate, with an average rating of approximately 5.7 out of 10. PatientsLikeMe reports from users with osteoporosis show tolerability as the primary reason for discontinuation, not lack of efficacy. Reddit threads in r/osteoporosis, r/Menopause, and r/ChronicPain surface similar patterns. None of these samples are random or controlled. They represent people who were motivated to share, which almost always means people who struggled.

GI Complaints: The Most Common Thread

The single most consistent complaint across every platform is upper gastrointestinal distress. Women describe heartburn that starts within an hour of taking the pill, a burning sensation behind the sternum, and nausea that lingers for the rest of the morning.

One frequently cited Reddit comment in r/Menopause reads: "I took it for six weeks and my esophagus felt like I had swallowed sandpaper. My GI doc said the pill was probably sitting in my esophagus because I didn't stand up long enough."

That description matches the clinical mechanism precisely. Alendronate is directly caustic to esophageal mucosa if it does not clear the esophagus quickly. The FDA prescribing information for alendronate requires patients to take the tablet with a full 240 mL (8 oz) of plain water, remain upright for at least 30 minutes, and eat nothing for at least 30 minutes after dosing. Many women in reviews describe not having received this counseling clearly.

Musculoskeletal Pain: Underreported in Trials, Common in Reviews

A consistent theme in Drugs.com reviews is severe bone, joint, and muscle pain, sometimes starting within days of the first dose. This is not a fabricated complaint. The FDA issued a safety communication in 2008 noting that bisphosphonates, including alendronate, can cause severe and sometimes incapacitating musculoskeletal pain. The pain can appear within days, months, or years of starting treatment.

A practical clinical framework for women starting alendronate: if you develop new joint or bone pain in the first three months that is out of proportion to any prior pattern, contact your prescriber before dismissing it as coincidence. Stopping the drug often resolves the pain, though it can take weeks.

Jaw Pain and ONJ: How Common Is It Really?

Osteonecrosis of the jaw (ONJ) generates significant anxiety in reviews and on Reddit, with women posting about their fears before dental procedures. The risk is real but much lower for oral alendronate used for osteoporosis than for intravenous bisphosphonates used in cancer treatment. Estimates for ONJ risk with oral bisphosphonates for osteoporosis range from roughly 1 in 10,000 to 1 in 100,000 patient-treatment years, compared with 1 to 10 percent in oncology patients on high-dose IV bisphosphonates.

Women in forums often describe dentists refusing to do extractions or implants once they see bisphosphonate use in the chart. The American Dental Association's guidance does not recommend stopping oral bisphosphonates before routine dental procedures in low-risk patients, though this remains a clinical judgment call.

Atypical Femur Fractures: A Real but Rare Signal

Atypical subtrochanteric femur fractures, where the thigh bone breaks with minimal trauma in an unusual location, have been linked to long-term bisphosphonate use. FDA updated alendronate labeling in 2010 to include this warning. The absolute risk is low, estimated at fewer than 100 cases per 100,000 person-years even after 5 to 10 years of use, but women using alendronate for more than five years should discuss this risk with their clinician at each annual review.

Fosamax Across Life Stages: Who Benefits and Who Should Not Take It

Postmenopausal Women (Most Common Users)

Postmenopausal estrogen loss accelerates bone resorption sharply. Women lose roughly 2 to 3 percent of bone mass per year in the first five to seven years after menopause. Alendronate directly counters this by suppressing osteoclast activity. For postmenopausal women with a DEXA T-score of -2.5 or below, or a T-score between -1.0 and -2.5 with a 10-year FRAX hip fracture probability of 3 percent or greater, alendronate is a first-line option.

GI tolerability problems are more common in older postmenopausal women who also take NSAIDs for arthritis, have reflux disease, or take other medications that slow gastric motility.

Perimenopausal Women (Reproductive Years Transitioning)

Alendronate is not typically started during perimenopause unless there is documented osteoporosis by T-score or a fragility fracture. Bone loss during perimenopause is real but usually less severe than the sharp postmenopausal drop. For perimenopausal women with osteopenia, lifestyle measures and possibly menopausal hormone therapy are usually addressed first. The Menopause Society notes that estrogen-based therapy is an FDA-approved alternative for osteoporosis prevention in postmenopausal women who are also appropriate candidates for MHT.

Women of Reproductive Age with Glucocorticoid-Induced Osteoporosis

Alendronate 5 mg daily (or 35 mg weekly) is FDA-approved for glucocorticoid-induced osteoporosis in both men and women. Women with conditions like lupus, rheumatoid arthritis, or inflammatory bowel disease who need long-term steroids may be prescribed alendronate during their reproductive years. This creates a pregnancy risk scenario that requires explicit contraception counseling (see next section).

Pregnancy, Lactation, and Contraception: What Every Woman Needs to Know

Alendronate is contraindicated in pregnancy. This is not a theoretical caution. Bisphosphonates bind to fetal bone and animal studies demonstrate skeletal abnormalities at doses lower than the human therapeutic dose. The drug's half-life in bone is estimated at 10 years or longer, meaning it persists in your skeleton long after you stop taking it, and can theoretically transfer to a developing fetus during a future pregnancy.

FDA Pregnancy Status

Alendronate carries FDA Pregnancy Category C (older classification) / no assigned letter under the current labeling system, with animal data showing fetal harm and no adequate, well-controlled human trials. Given the pharmacokinetics, even a pregnancy years after stopping the drug could involve fetal exposure from bone stores.

A 2008 case series in Fertility and Sterility documented outcomes in women who became pregnant while on or shortly after bisphosphonate therapy; outcomes were generally reassuring for short inadvertent exposures, but the series was small and not designed to detect rare malformations.

Lactation

Alendronate has not been adequately studied in human lactation. The drug's low oral bioavailability (less than 1 percent) may limit infant exposure through breast milk, but no reliable pharmacokinetic data in lactating women exists. Given the absence of safety data, most clinicians advise against using alendronate while breastfeeding.

Contraception Requirement

Any woman of reproductive age who is prescribed alendronate for glucocorticoid-induced osteoporosis or another indication should use reliable contraception throughout treatment and discuss with her prescriber how long to continue contraception after stopping, given the drug's skeletal half-life. This conversation is rarely had clearly enough in practice, and it is a gap worth raising directly with your prescriber.

Who This Drug Is Right For, and Who Should Think Twice

Good Candidates

Women who are likely to do well on alendronate share a few characteristics. They are postmenopausal with confirmed low bone density by DEXA. They do not have active upper GI disease, esophageal stricture, or Barrett's esophagus. They can reliably remain upright for at least 30 minutes after taking the tablet. They are not planning pregnancy. They are not taking NSAIDs daily, which compound GI mucosal injury.

Women Who Should Consider Alternatives

If you have active reflux disease, esophagitis, or a history of esophageal problems, your clinician may prefer a different bisphosphonate route (intravenous zoledronic acid once yearly, for example) or a different drug class entirely, such as denosumab or raloxifene. Raloxifene (Evista) is an alternative for postmenopausal women who cannot tolerate oral bisphosphonates and has the added benefit of reducing breast cancer risk, though it carries its own risks including venous thromboembolism.

Women with a creatinine clearance below 35 mL/min should not use alendronate, as renal impairment prevents safe clearance of the drug.

How to Take Alendronate to Minimize Side Effects

The dosing ritual matters more for this drug than almost any other common prescription. Getting it wrong does not just reduce efficacy; it can injure your esophagus.

The Non-Negotiable Morning Protocol

Take the 70 mg weekly tablet first thing in the morning, before any food, drink (other than plain water), or other medication. Use a full 8-ounce glass of plain water. Do not use mineral water, coffee, juice, or anything else. Calcium and other minerals in beverages bind alendronate and reduce absorption to near zero. Stay fully upright, either sitting up straight or standing, for at least 30 minutes. Then wait at least 30 more minutes before eating breakfast.

Do not lie down. Even reclining in bed with pillows is not adequate. The tablet must clear the esophagus by gravity and peristalsis before it can cause damage.

If You Forget a Dose

With the once-weekly 70 mg regimen, take the missed dose on the morning of the next day you remember, then return to your regular weekly schedule. Do not take two tablets on the same day.

Supplements and Timing

Calcium supplements, antacids, and most vitamins contain minerals that interfere with absorption. Take them at a different time of day, at least two hours after your alendronate dose.

The Honest Picture on Reviews: What Selection Bias Means for You

WomanRx editorial board member Rachel Goldberg, MD, put it plainly in a recent clinical review session: "I tell patients that if they Google Fosamax reviews, they will read horror stories and conclude the drug is dangerous. What those reviews don't capture is the woman who took it for seven years without a side effect and never broke a hip, because she had no reason to post anything."

That asymmetry is measurable. In the FIT trial, the rate of upper GI adverse events leading to discontinuation in the alendronate group was 3.2 percent versus 2.4 percent in placebo, a statistically significant but clinically modest difference. In online reviews, the narrative is dominated by that minority, not the majority who tolerated the drug.

This does not mean the bad experiences are fabricated or unimportant. The esophageal injury risk is real. The musculoskeletal pain signal is real. Jaw and femur risks, while rare, are real. Knowing what to watch for, and what the actual frequencies are, is more useful than either dismissing the reviews entirely or letting them drive you away from a drug that may prevent a hip fracture.

Monitoring and Follow-Up: What Should Happen After You Start

A DEXA scan at baseline before starting alendronate is standard practice. ACOG recommends a repeat DEXA scan after 1 to 2 years of therapy to confirm response. If BMD is stable or improving, the drug is working. If it continues to fall despite treatment, the diagnosis of secondary osteoporosis should be revisited, or a different drug class considered.

Bone turnover markers, specifically serum C-telopeptide (CTX) or urine N-telopeptide (NTX), can confirm that the drug is suppressing bone resorption within three to six months, before any BMD change is visible on DEXA. This is particularly useful for women who want biochemical confirmation that the drug is doing something.

Dental care while on alendronate does not need to stop. Routine cleanings, fillings, and crowns carry no meaningful ONJ risk. Extractions and implants in women on long-term therapy warrant a conversation with both your dentist and prescriber, but the risk remains low in oral bisphosphonate users compared with IV oncology doses.

At the five-year mark, discuss the drug holiday option with your clinician. For women with moderate fracture risk, stopping alendronate for 1 to 2 years may preserve the anti-fracture benefit accumulated during treatment, while reducing the cumulative risk of rare long-term side effects.